Table 2.
| Developer | Technology |
|---|---|
| CaroGen Corp. | VLV-based nanoparticle |
| CDC | VLP expressed by DNA plasmid; live recombinant adenovirus |
| GeoVax Labs, Inc. | MVA-VLP technology elicits antibodies and T cells |
| Hawaii Biotech | Recombinant proteins produced from insect cell line, plus Alhydrogel or proprietary adjuvant |
| Inovio/GeneOne Life Science | DNA (electroporation) |
| Kansas State University | DNA |
| NewLink Genetics Corp. | Purified inactivated virus |
| NIH | Zika-targeted mutation, live attenuated (longer-term); DNA; live VSV recombinant |
| Novavax | E protein (nanoparticles) |
| Pharos Biologicals, Inc. | Nanosphere delivery |
| Protein Sciences Corp. | Recombinant variations of Zika virus E protein |
| Replikins, Ltd. | Synthetic replilink peptides |
| Vaxart, Inc. | Recombinant Zika vaccine in room temperature-stable tablets |
| VaxInnate Corp. | TLR technology; vaccine antigens are genetically fused to bacterial protein flagellin |
| Xenetic Biosciences | Combined Zika/dengue vaccine |
CDC = Centers for Disease Control and Prevention; MVA = modified vacinnia Ankara; NIH = National Institutes of Health; TLR = toll-like receptor; VLP = virus-like particle; VLV = virus-like vesicle; VSV = vesicular stomatitis virus.